Figure 2From: Cyclin-dependent kinase-specific activity predicts the prognosis of stage I and stage II non-small cell lung cancer Analysis of recurrence and survival by risk category. (A) Recurrence-free survival and (B) overall survival according to CDK1SA-based risk with a cut-off value of 12.6 maU/eU. (C) Recurrence- free survival and (D) overall survival according to CDK2SA-based risk with a cut-off value of 222 maU/eU.Back to article page